WO1996028168A1 - Methods for the treatment of thrombosis - Google Patents
Methods for the treatment of thrombosis Download PDFInfo
- Publication number
- WO1996028168A1 WO1996028168A1 PCT/US1995/003429 US9503429W WO9628168A1 WO 1996028168 A1 WO1996028168 A1 WO 1996028168A1 US 9503429 W US9503429 W US 9503429W WO 9628168 A1 WO9628168 A1 WO 9628168A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- platelet
- patient
- aspirin
- citric acid
- platelet aggregation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
- A61K31/621—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Definitions
- This invention relates to methods and compositions for the treatment or prophylaxis of thrombosis. More particularly, this invention provides methods and compositions for reducing platelet aggregation in the circulating blood of a patient.
- Thrombus formation involves a complex interaction of aggregated platelets and activated coagulation factors with the damaged vessel wall. Circulating non- activated platelets do not adhere to normal endothelium or to each other, but when the endothelial lining of a vessel is broken, such platelets adhere to the exposed subendothelial collagen. This is the first step in the formation of hemostatic plugs, and requires participation of a protein made by endothelial cells called the von Willebrand (vW) factor. The vW factor is found both in the vessel wall and in plasma, and binds during platelet adhesion to a receptor present on the platelet surface membrane. Next, platelets are activated in reactions initiated by collagen and by thrombin formed at the injury site.
- vW von Willebrand
- Arachidonic acid is liberated from membrane phospholipids and undergoes oxidation to products that include prostaglandin H 2 (PGH 2 ), which serves as an important cofactor for collagen-induced platelet activation, and thromboxane A 2 (TxA 2 ), which can act itself as an additional platelet activator.
- PSH 2 prostaglandin H 2
- TxA 2 thromboxane A 2
- the contents of platelets are secreted, including adenosine diphosphate (ADP) which can also stimulate platelet activation and recruit new platelets into the growing hemostatic plug.
- ADP adenosine diphosphate
- fibrinogen in the circulating blood is converted to fibrin to physically tie the hemostatic platelet plug in place.
- the platelet surface undergoes a reorganization that exposes procoagulant phospholipids needed for enzyme/cofactor complexes of blood coagulation to form on the platelet surface.
- Secretion of platelet factor V from platelet a-granules provides a key component for one of the enzyme/cofactor complexes.
- thrombin is generated in increasing amounts on the platelet surface, and converts fibrinogen into fibrin with the formation of fibrin strands that radiate outward from aggregated platelets helping to secure the platelet plug to the site of injury.
- a mechanism within the platelets is activated which results in contraction of platelet actinomycin. This compresses and consolidates the platelet plug, further securing it to the site of injury.
- platelet aggregation is mediated by the PGH 2 derivative prostacyclin (PGI 2 ).
- PGI 2 prostacyclin
- Prostacyclin is also a vasodilator and is believed to render the vessel lining inert to platelet interactions.
- TxA 2 and PGI 2 have opposing effects on platelet aggregation, and the degree of the physiological effect of each in the cardiovascular system on the regulation of thrombus formation is determined mainly by their quantitative balance (Bush, H.L., Jr.
- PGG 2 is a precursor to both TxA 2 and PGI 2 , aspirin blocks both the aggregation inducing and aggregation inhibiting effects of these factors, respectively.
- aspirin As an antithrombotic agent, aspirin has had varying degrees of success. Although minimal amounts of aspirin are required for platelet inhibition, most of the clinical experience relates to relatively large doses. The nonselective, potent inhibition of high-dose aspirin on both TxA 2 and PGI 2 has caused investigators to consider the theoretical advantage of the use of low-dose therapy. Preferred inhibition of proaggregatory TxA 2 in humans has been limited to single-dose aspirin administration or short-term cumulative effect.
- aspirin has little or no discernable antiaggregatory activity, and is not effective in reducing a predisposition for thrombus formation.
- TTIs thromboxane synthetase inhibitors
- imidazole derivatives have been proposed for this purpose, for use either alone or in connection with low dose aspirin therapy. See, for example, Kaplan, S. et al., "A New Combination Therapy for Selective and Prolonged Antiplatelet Effect: Results in the Dog," Stroke, 17:450-454 (1986). It has also been suggested that zinc ions exhibit an inhibitory activity toward collagen-induced platelet aggregation and serotonin release in vitro (Chapvil, M.
- compositions comprising aspirin and citric acid, and optionally a pharmaceutically acceptable zinc salt.
- aspirin and citric acid has been found to be significantly more effective in inhibiting platelet aggregability than aspirin alone. Accordingly, new methods are disclosed for reducing the platelet aggregability of human or animal subjects. The new methods are highly effective in the treatment of cardiovascular patients, such as in the prophylaxis or treatment of the thrombotic complications of atherosclerosis.
- FIGURE 1 is a graph of a representative adenosine diphosphate (ADP)-induced platelet aggregation response showing the percent of light transmission through platelet rich plasma (PRP) as a function of time after induction of aggregation; and
- ADP adenosine diphosphate
- FIGURE 2 is a graph of the ADP-induced in vitro platelet aggregation response in PRP with no treatment (baseline, represented by solid dots), and after exposure to sodium citrate (open squares), aspirin and sodium citrate (closed squares), aspirin alone (open circles), citric acid (closed triangles), aspirin and citric acid (open triangles), water alone (dotted line) or water and ethanol (dashed line).
- one aspect of the present invention provides a method for reducing a predisposition for thrombus formation in a patient comprising administering to the patient a therapeuticaliy effective amount of a composition comprising aspirin and citric acid.
- a patient is treated by administering to the patient amounts of aspirin, citric acid, and optionally a zinc salt, effective to reduce platelet aggregation, thereby decreasing the likelihood of thrombus formation by at least partially blocking the platelet aggregation pathway.
- compositions comprising an amount of aspirin and citric acid effective to reduce platelet aggregation when administered to a patient.
- the compositions of the invention comprise aspirin, citric acid and a zinc salt.
- compositions of the invention may be used prophylactically or therapeuticaliy in the treatment of patients who are at high risk of thrombus formation, such as in the treatment of atherosclerosis, vascular surgery patients, and patients with other types of cardiovascular disease.
- amounts of acetylsalicylic acid and citric acid effective to reduce platelet aggregation are administered to the patient.
- Effective but nontoxic amounts of acetylsalicylic acid and citric acid may be readily determined by the ordinary skilled physician. The precise amounts required for this purpose will depend upon the body weight of the patient, physiological condition of the patient, thrombotic potential of the patient, desired effect, and other factors.
- At least about 0.5 mg of acetylsalicylic acid per kg of body weight of the patient per day, more preferably from about 2 to about 4 mg of acetylsalicylic acid per kg of body weight of the patient per day, and at least about 0.5 mg of citric acid per kg of body weight of the patient per day, more preferably from about 2 to about 4 mg of citric acid per kg of body weight of the patient per day is administered to the patient.
- a patient is treated in accordance with the foregoing and by additionally administering to the patient an amount of a pharmaceutically acceptable zinc salt effective to result in a reduction in platelet aggregability of the patient.
- a pharmaceutically acceptable zinc salt effective to result in a reduction in platelet aggregability of the patient.
- at least about 0.01 mg of the zinc salt per kg of body weight of the patient per day will be effective for this purpose, but significantly larger doses may be employed, if desired.
- Suitable zinc salts include, for example, the pharmaceutically acceptable acid addition salts of Zn 2+ , such as the hydrochloric, sulfuric, phosphoric, acetic, citric, oxalic, malonic, salicylic, malic, gluconic, fumaric, succinic, ascorbic, maleic, methanesulfonic, arginine or similar pharmaceutically acceptable salts.
- the pharmaceutically acceptable acid addition salts of Zn 2+ such as the hydrochloric, sulfuric, phosphoric, acetic, citric, oxalic, malonic, salicylic, malic, gluconic, fumaric, succinic, ascorbic, maleic, methanesulfonic, arginine or similar pharmaceutically acceptable salts.
- Presently particularly preferred salts include zinc acetate and zinc sulfate.
- compositions which comprise amounts of acetylsalicylic acid and citric acid effective to reduce platelet aggregation and an amount of a pharmaceutically acceptable zinc salt effective to result in a reduction in platelet aggregability of the patient, as described above, as well as pharmaceutically acceptable carriers.
- Preferred compositions of the invention are designed for unit dosage administration, such as, for example, for routine one dose a day administration, and may contain representative amounts of the active compounds within the following ranges:
- compositions of the invention comprise from about 100 to about
- compositions may additionally comprise from about 0.5 to about 2 mg dose of a pharmaceutically acceptable zinc salt.
- compositions of the invention can be administered in any effective pharmaceutically acceptable form to warm blooded animals, e.g., in oral, parenteral or infusible dosage forms, in transdermal formulations or as a buccal or nasal spray.
- suitable parenteral routes of administration include, for example, intramuscular, intravenous, intraperitoneal or subcutaneous administration of the compounds. For most purposes, oral administration will be preferred.
- Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules.
- the active compounds may be admixed with at least one inert diluent such as sucrose, lactose or starch.
- Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., lubricating agents such as magnesium stearate.
- the dosage forms may also comprise buffering agents. Tablets and pills may additionally be prepared with enteric coatings.
- Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs containing inert diluents commonly used in the art, such as water. Besides such inert diluents, compositions of the may also comprise adjuvants such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring and perfuming agents.
- compositions according to the invention for parenteral injection may comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, suspensions or emulsions.
- suitable nonaqueous carriers, diluents, solvents or vehicles include propylene glycol, polyethylene glycol, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate.
- Such compositions may also contain adjuvants, such as preserving, wetting, emulsifying and dispersing agents. They may be sterilized, for example, by filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the compositions. They can also be manufactured in the form of sterile solid compositions which can be dissolved in sterile water, or other sterile injectable medium, immediately before use.
- platelet aggregations were performed on a Payton dual channel aggregometer with an Omniscribe B-5000 chart recorder with platelet rich plasma (PRP) prepared from venous blood anticoagulated with 3.8% sodium citrate according to the turbidometric method of Born, GVR, "Aggregation of Blood Platelets by Adenosine Diphosphate and Its Reversal," Nature, 194:927-929 (1962). Platelet aggregations were induced with adenosine diphosphate (ADP).
- PRP platelet rich plasma
- FIGURE 1 a typical adenosine diphosphate-induced platelet aggregation curve depicting percent transmission (%Tran) as a function of time
- Example 1 Sixteen human patients shown to have an inadequate platelet aggregation response to aspirin administration alone, were given daily doses of a composition having the following formulation: aspirin 158 mg citric acid 158 mg thiamine hydrochloride 8 mg zinc acetate 1 mg
- Example 3 Six human patients were selected for treatment after experiencing one or more occurrences of thrombotic vascular occlusion following vascular surgery.
- the thrombotic condition of each subject was clinically determined to be inadequately controlled by conventional aspirin therapy.
- Each of the six subjects was judged to be at high risk of subsequent vascular occlusions, and of significant potential for loss of life or limb.
- Each subject was placed on a daily treatment regimen of a single dose of the composition of Example 1. All of the subjects were routinely examined, and remained free from clinically observable thrombotic occlusions from beginning the treatment regimen for periods extending from two months to over 12 months. Each subject remained free from complications associated with their prior symptoms, and were judged to have avoided significant hospitalization and medical care which would have otherwise been required.
- the therapeutic effects of the practice of the invention in most human and animal subjects have included a dramatic inhibition of platelet aggregation, together with a resulting substantial decrease or elimination of thrombotic occlusion events.
- the inhibitory action of the compositions of the invention on platelet activity has been shown to be much more effective than that elicited by aspirin alone.
- the subjective clinical experience in patients treated according to the invention has been highly favorable as judged by lack of symptoms, a relative freedom from complications and an overall higher quality of life, which is in marked contrast to their pretreatment state.
- the methods and compositions of the invention therefore provide a safe, effective means for the long-term, on-going prophylactic or therapeutic treatment of patients having a predisposition for life threatening thrombus formation, where adequate chronic treatment has heretofore been unavailable.
- Example 4 A single center, double blind study was designed to test the hypothesis that daily administration of a combination of aspirin (acetylsalicylic acid, ASA) and citric acid provides greater inhibition of platelet aggregation than ASA therapy alone.
- aspirin acetylsalicylic acid, ASA
- citric acid provides greater inhibition of platelet aggregation than ASA therapy alone.
- Platelet aggregation responses were measured using the turbidimetric procedure of Born, "Aggregation of Blood Platelets by Adenosine Diphosphate and its Reversal," Nature 4832:927-929 (1962), and quantified by the platelet aggregation scoring method of Saad et al., "Platelet Aggregometry Can Accurately Predict Failure of Externally Supported Knitted Dacron Femoropopliteal Bypass Grafts," J. Vascular Surgery 18(4):587-594 (1993).
- Those individuals having a base line platelet aggregation (PA) score above 30 were invited back to be retested after ingesting 325 mg of ASA daily for a minimum of three days. Volunteers with ASA medicated PA scores remaining above 30 were asked to continue participating in the study. Twenty-four volunteers, 15 men and 9 post-menopausal women, were enrolled in the next phase of the study.
- Each person enrolled in the study was instructed to not take ASA-containing products throughout their participation in the study.
- Each person in the study was randomly placed in one of four groups, with each group being designated to receive daily administration of one of the following four medications:
- the foregoing medication was prescribed to be taken daily for a period of two weeks, and platelet aggregation analyses for each participant were performed at the beginning and end of the two-week treatment period, as described below.
- a two-week non- medicated rest period was prescribed following the treatment period, and then each patient was randomly placed into another one of the four groups identified above. The foregoing procedure was repeated until each study participant had participated in each of the four study groups.
- all four medications were placed in identical looking gelatin capsules, and participants were unaware of the capsule contents. The order and sequence of medication distribution were unknown to the study participants. Individuals were assigned a medication sequence in the order they were recruited. Medications were prepared and distributed by a research chemist not involved in sample collection and platelet aggregation analysis.
- Blood drawing and scheduling appointments was handled by a phlebotomist who was not involved in distribution of the capsules or platelet aggregation analysis. Platelet aggregation tests were performed by a research associate who was not involved in capsule distribution or blood sample collection, on coded samples which did not reveal the participant group or medication taken. At the completion of data collection for all 24 participants, the data collected was analyzed.
- the platelet aggregation of each participant was determined as follows. Using the standard venipuncture technique fasted blood was collected in a 5 mL vacutainer tube (Becton Dickinson Co., Rutherford, NJ) with EDTA Na 2 for the actual platelet count determination. Two 4.5 mL vacutainer tubes with 3.8% buffered sodium citrate were drawn for aggregation studies.
- Platelet-rich plasma was prepared from the citrated blood by centrifugation sufficient to sediment the red and white cells. After reserving an aliquot of the platelet-rich plasma supernatant, the blood was centrifuged again, at higher speed, to clear platelets into the pellet, yielding a platelet-poor plasma supernatant.
- a test plasma sample for aggregometry was prepared by diluting the aliquot of platelet-rich plasma with platelet-poor plasma, until the sample had a platelet count of 250,000 ⁇ 25,000/mm 3 .
- ADP Adenosine diphosphate
- a standard transmission span of 10% and 90% was used for the platelet-poor plasma and platelet-rich plasma, respectively, and the test time was fixed at eight minutes.
- Adenosine diphosphate (ADP) reagent (Dade Laboratories, Miami, FL) was prepared daily by reconstitution with distilled water according to the manufacturer's instructions. After 450 ⁇ L of the standardized plasma sample had been incubated in a Chrono-log 560 VS aggregometer with a 707 recorder (Chrono-log Corp., Havertown, PA) driven by a Fluke 1752 A Data Acquisition System (John Fluke Mfg.
- the platelet aggregation (PA) score of each sample was obtained by the following formula:
- PA score Amp R • S ⁇ ⁇ Pit R
- Table 3 shows the p-values for a comparison of the treatments.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU21032/95A AU2103295A (en) | 1993-04-22 | 1995-03-15 | Methods for the treatment of thrombosis |
EP95913770A EP0814814A4 (en) | 1993-04-22 | 1995-03-15 | Methods for the treatment of thrombosis |
JP8527542A JPH11507325A (en) | 1993-04-22 | 1995-03-15 | Methods for treating thrombosis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/052,219 US5401730A (en) | 1990-07-06 | 1993-04-22 | Method for reducing platelet aggregation |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996028168A1 true WO1996028168A1 (en) | 1996-09-19 |
Family
ID=21976172
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/003429 WO1996028168A1 (en) | 1993-04-22 | 1995-03-15 | Methods for the treatment of thrombosis |
Country Status (5)
Country | Link |
---|---|
US (1) | US5401730A (en) |
EP (1) | EP0814814A4 (en) |
JP (1) | JPH11507325A (en) |
AU (1) | AU2103295A (en) |
WO (1) | WO1996028168A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001003774A2 (en) * | 1999-07-07 | 2001-01-18 | Dardai Zoltan | Pharmaceutical composition for the treatment of calcification |
WO2002076482A2 (en) * | 2001-03-27 | 2002-10-03 | Procorde Gmbh | USE OF IKK-β INHIBITORS AND METHOD FOR DISCOVERY OF SAID INHIBITORS |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6251920B1 (en) | 1993-05-13 | 2001-06-26 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
JPH08510451A (en) | 1993-05-13 | 1996-11-05 | ネオルックス コーポレイション | Prevention and treatment of pathogenesis associated with hyperproliferative smooth muscle cells |
EP0821587A4 (en) * | 1995-04-19 | 1999-05-19 | Lipoprotein Technologies Inc | Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs |
AU6277396A (en) * | 1995-06-07 | 1996-12-30 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies with tamoxifen analogues |
FR2740335B1 (en) * | 1995-10-26 | 1997-12-19 | Oreal | USE OF LANTHANIDE, LITHIUM, TIN, ZINC, MANGANESE OR YTTRIUM SALT AS A SUBSTANCE P ANTAGONIST |
US5770215A (en) * | 1997-01-06 | 1998-06-23 | Moshyedi; Emil Payman | Multivitamin/vascular occlusion inhibiting composition |
AU6959898A (en) | 1997-04-11 | 1998-11-11 | David J. Grainger | Compounds and therapies for the prevention of vascular and non-vascular pathol ogies |
US6121249A (en) * | 1998-07-01 | 2000-09-19 | Donald L. Weissman | Treatment and prevention of cardiovascular diseases with help of aspirin, antioxidants, niacin, and certain B vitamins |
US6274170B1 (en) | 1999-02-18 | 2001-08-14 | Richard Heibel | Compounds for cardiovascular treatment comprising multi-vitamin and anti-platelet aggregating agents and methods for making and using the same |
DE19959913A1 (en) * | 1999-12-11 | 2001-06-28 | Lohmann Therapie Syst Lts | Transdermal system for the treatment of migraines containing acetylsalicylic acid |
US7208180B2 (en) * | 2000-05-08 | 2007-04-24 | N.V. Nutricia | Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith |
US7226916B1 (en) | 2000-05-08 | 2007-06-05 | N.V. Nutricia | Preparation for the prevention and/or treatment of vascular disorders |
EP1350511B1 (en) * | 2000-12-25 | 2008-09-10 | Daiichi Sankyo Company, Limited | Medicinal compositions containing aspirin |
AU2003284337B2 (en) * | 2002-10-25 | 2010-04-15 | Precision Dermatology, Inc. | Modulation of zinc levels to improve tissue properties |
GB2407040B (en) * | 2003-10-15 | 2007-09-19 | Sheikh Arshad Saeed | Anti-platelet aggregation compositions |
FI20040136A0 (en) * | 2004-01-30 | 2004-01-30 | Faron Pharmaceuticals Oy | Compositions especially suitable for diabetics |
WO2006096356A1 (en) * | 2005-03-08 | 2006-09-14 | Neurosci, Inc. | Compositions for inhibiting and preventing vascular occlusion containing nutritional supplements |
ES2507070T3 (en) | 2006-02-03 | 2014-10-14 | Omp, Inc. | Anti-aging treatment using copper and zinc compositions |
US7897800B2 (en) | 2006-02-03 | 2011-03-01 | Jr Chem, Llc | Chemical compositions and methods of making them |
US7687650B2 (en) | 2006-02-03 | 2010-03-30 | Jr Chem, Llc | Chemical compositions and methods of making them |
US7867522B2 (en) | 2006-09-28 | 2011-01-11 | Jr Chem, Llc | Method of wound/burn healing using copper-zinc compositions |
US8273791B2 (en) | 2008-01-04 | 2012-09-25 | Jr Chem, Llc | Compositions, kits and regimens for the treatment of skin, especially décolletage |
WO2010085753A1 (en) | 2009-01-23 | 2010-07-29 | Jr Chem, Llc | Rosacea treatments and kits for performing them |
US8952057B2 (en) | 2011-01-11 | 2015-02-10 | Jr Chem, Llc | Compositions for anorectal use and methods for treating anorectal disorders |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3904761A (en) * | 1974-01-25 | 1975-09-09 | Hoechst Co American | Method of preventing thrombosis |
US4193813A (en) * | 1976-09-07 | 1980-03-18 | Medi-Coll, Inc. | Method for making collagen sponge |
US4845129A (en) * | 1988-03-14 | 1989-07-04 | Sandoz Pharm. Corp. | Diaryl substituted cyclopentane and cyclopentene derivatives |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3842169A (en) * | 1970-09-14 | 1974-10-15 | H Schneyer | Composition and method for treatment of pathological calcification in animals |
FR2307538A1 (en) * | 1975-04-18 | 1976-11-12 | Centre Etd Ind Pharma | NEW PLATELET ANTI-AGGREGANT DRUG |
DE2549998A1 (en) * | 1975-11-07 | 1977-05-12 | Merck Patent Gmbh | MEANS OF INHIBITING THROMBOCYTE AGGREGATION |
DE3535947A1 (en) * | 1985-10-09 | 1987-04-09 | Basf Ag | COMBINATION PREPARATION |
EP0372676A1 (en) * | 1988-12-08 | 1990-06-13 | Spyros Carantinos | Therapeutic preparation and method |
DE3935550A1 (en) * | 1989-10-25 | 1991-05-02 | Pharmatrans Sanaq Ag | Chewable or suckable medicine, process for its manufacture and its use |
CN1105237A (en) * | 1994-10-15 | 1995-07-19 | 孙素波 | Aspirin chewing gum |
-
1993
- 1993-04-22 US US08/052,219 patent/US5401730A/en not_active Expired - Fee Related
-
1995
- 1995-03-15 AU AU21032/95A patent/AU2103295A/en not_active Abandoned
- 1995-03-15 WO PCT/US1995/003429 patent/WO1996028168A1/en not_active Application Discontinuation
- 1995-03-15 JP JP8527542A patent/JPH11507325A/en active Pending
- 1995-03-15 EP EP95913770A patent/EP0814814A4/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3904761A (en) * | 1974-01-25 | 1975-09-09 | Hoechst Co American | Method of preventing thrombosis |
US4193813A (en) * | 1976-09-07 | 1980-03-18 | Medi-Coll, Inc. | Method for making collagen sponge |
US4845129A (en) * | 1988-03-14 | 1989-07-04 | Sandoz Pharm. Corp. | Diaryl substituted cyclopentane and cyclopentene derivatives |
Non-Patent Citations (2)
Title |
---|
BIOLOGICAL ABSTRACTS, Volume 91, No. 7, issued 01 April 1991, LIN et al., "Study on the Effect of Various Conditions and Age to Blood Platelet Aggregation Test", page 80, Abstract No. 69072; & KAOHSIUNG J. MED. SCI., 6(12): 636-642. * |
See also references of EP0814814A4 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001003774A2 (en) * | 1999-07-07 | 2001-01-18 | Dardai Zoltan | Pharmaceutical composition for the treatment of calcification |
WO2001003774A3 (en) * | 1999-07-07 | 2002-03-21 | Zoltan Dardai | Pharmaceutical composition for the treatment of calcification |
WO2002076482A2 (en) * | 2001-03-27 | 2002-10-03 | Procorde Gmbh | USE OF IKK-β INHIBITORS AND METHOD FOR DISCOVERY OF SAID INHIBITORS |
WO2002076482A3 (en) * | 2001-03-27 | 2003-09-25 | Procorde Gmbh | USE OF IKK-β INHIBITORS AND METHOD FOR DISCOVERY OF SAID INHIBITORS |
Also Published As
Publication number | Publication date |
---|---|
EP0814814A4 (en) | 1999-01-13 |
AU2103295A (en) | 1996-10-02 |
EP0814814A1 (en) | 1998-01-07 |
US5401730A (en) | 1995-03-28 |
JPH11507325A (en) | 1999-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1996028168A1 (en) | Methods for the treatment of thrombosis | |
DeCaterina et al. | Vascular prostacyclin is increased in patients ingesting omega-3 polyunsaturated fatty acids before coronary artery bypass graft surgery. | |
TULLOCH et al. | Long-term anticoagulant therapy: further experiences | |
Lorenz et al. | Improved aortocoronary bypass patency by low-dose aspirin (100 mg daily): effects on platelet aggregation and thromboxane formation | |
Gavaghan et al. | Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery. A placebo-controlled, randomized study. | |
Weiss et al. | Role of shear rate and platelets in promoting fibrin formation on rabbit subendothelium. Studies utilizing patients with quantitative and qualitative platelet defects. | |
Serneri et al. | Effectiveness of low-dose heparin in prevention of myocardial reinfarction | |
Ridker et al. | The effect of chronic platelet inhibition with low-dose aspirin on atherosclerotic progression and acute thrombosis: clinical evidence from the Physicians' Health Study | |
Baur et al. | Effects of sulfinpyrazone on early graft closure after myocardial revascularization | |
Chaplin Jr et al. | Aspirin-dipyridamole prophylaxis of sickle cell disease pain crises | |
BG64542B1 (en) | PHARMACEUTICAL COMPOSITION COMPRISING A COMPOUND HAVING ANTI-Xa ACTIVITY AND A PLATELET AGGREGATIION ANTAGONIST COMPOUND | |
Weiss | Brief Report: Aspirin Ingestion Compared with Bleeding Disorders—Search for a Useful Platelet Antiaggregant | |
van der Meer et al. | A comparison of internal mammary artery and saphenous vein grafts after coronary artery bypass surgery. No difference in 1-year occlusion rates and clinical outcome. CABADAS Research Group of the Interuniversity Cardiology Institute of The Netherlands. | |
Walker et al. | A double blind study of prostacyclin in cardiopulmonary bypass surgery | |
Makhoul et al. | Management of patients with heparin-associated thrombocytopenia and thrombosis requiring cardiac surgery | |
Brezinski et al. | Anti-ischemic actions of a new throm☐ ane receptor antagonist during acute myocardial ischemia in cats | |
Louie et al. | Diadenosine 5′, 5‴-P1, P4-tetraphosphate, a potential antithrombotic agent | |
Shapiro et al. | Postoperative thrombo-embolization: the platelet count and the prothrombin time after surgical operations: a simple method for detecting reductions and elevations of the prothrombin concentration (or activity) of the blood plasma | |
Hansen et al. | Inhibition of exercise-induced shortening of bleeding time by fish oil in familial hypercholesterolemia (type IIa). | |
Galt et al. | Flow cytometric assessment of platelet function in patients with peripheral arterial occlusive disease | |
Rothlin et al. | Platelet inhibitors versus anticoagulants for prevention of aorto-coronary bypass graft occlusion | |
Ninnemann et al. | The effect of plasma exchange on lymphocyte suppression after burn | |
Numano et al. | Antiaggregative aspirin dosage at the affected vessel wall | |
Dale et al. | Can acetylsalicylic acid alone prevent arterial thromboembolism? A pilot study in patients with aortic ball valve prostheses | |
Shea et al. | The beneficial effects of nafazatrom (BAYg6575) on experimental coronary thrombosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NL NO NZ PL PT RO RU SD SE SG SI SK TJ TT UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
ENP | Entry into the national phase |
Ref document number: 2215336 Country of ref document: CA Ref country code: CA Ref document number: 2215336 Kind code of ref document: A Format of ref document f/p: F Ref country code: JP Ref document number: 1996 527542 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995913770 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1995913770 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995913770 Country of ref document: EP |